Tessera Defense and Homeland Security Inc. HLSQ

Company Overview

BiomX Inc. is a clinical-stage biotechnology company focused on the discovery and development of precision phage therapies designed to target pathogenic bacteria associated with chronic diseases. The company operates within the biotechnology, microbiome, and infectious disease sectors, with a primary emphasis on bacteriophage-based therapeutics intended to treat conditions where antibiotic resistance or microbiome imbalance is a significant clinical challenge. BiomX’s core pipeline has included programs targeting cystic fibrosis-associated pulmonary infections, diabetic foot osteomyelitis, inflammatory bowel disease, and other microbiome-related disorders.

The company’s primary revenue and value drivers are tied to its therapeutic development pipeline, strategic collaborations, and intellectual property surrounding phage engineering and microbiome technologies. BiomX originated from microbiome and phage research conducted at the Weizmann Institute of Science and was formed through the merger of BiomX Ltd. and the publicly traded Chardan Healthcare Acquisition Corp. The company has positioned itself as a specialized developer of customized phage cocktails and precision bacterial targeting platforms, differentiating itself from broader antibiotic-focused biotechnology companies through its bacteriophage expertise and microbiome-oriented therapeutic strategy.